3] Nonstandard abbreviations: HER2, human growth factor receptor 2; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; FDA, US Food and Drug Administration; NCCTG
, North Central Cancer Treatment Group; NSABP, National Surgical Adjuvant Breast and Bowel Project; CEP17, chromosome 17 centromere enumerating probe.
was founded in 1977 on the premise that the community practice setting, where most cancer care occurs, is the most appropriate venue for conducting clinical trials.
In the NCCTG
trial, the delay between the completion of AC chemotherapy appeared to reduce the frequency of cardiac dysfunction.
Based on its safety and activity in non-Hodgkin's lymphoma, pixantrone has the potential to be an active agent in breast cancer that could be safely used in this setting, Singer further said and added that the company looks forward to the NCCTG
initiating this trial.
Phase III double-blind, randmnized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG
The tumor samples examined in the study came from NCCTG
N9831, a phase III randomized, multicenter clinical trial that tested adjuvant Herceptin given with, or following, chemotherapy with paclitaxel, compared with chemotherapy alone.
Phase Ill double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG
Furthermore, in the adjuvant setting, frequency of CNS metastasis as the first site of relapse was numerically greater in the trastuzumab arms in the HERA, NSABP B-31 and NCCTG
N9831 trials [32,33].
Perez EA, Romond EH, Suman VJ, et al: Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG
N9831 and NSABP B-31.
Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG
Tumor SPARC microenvironment signature (SMS) and plasma levels in a phase II trial of unresectable stage IV melanoma treated with nab-paclitaxel and carboplatin: a translational study of NCCTG
trial N057E (Abstract #8578)
Brief report: a phase II "window-of-opportunity" frontline study of the mTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG